Cite

HARVARD Citation

    Carbone, C. et al. (2016). Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment. Anti-cancer drugs. 27 (1), p. . [Online]. 
  
Back to record